Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

Merck swung to a fourth-quarter profit as sales grew and even exceeded Wall Street’s estimates, boosted in part by the ...

Merck’s problems in China seem to be getting worse, raising questions about the company’s growth. Trouble with sales of Merck ...

The drug company’s outlook for 2025 and a slide in sales of its HPV vaccine, Gardasil, hit shares.

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...

Blockbuster Keytruda makes up nearly half of Merck’s sales. That’s becoming an issue.

Merck has halted the phase 3 HYPERION trial of ... Winrevair garnered slightly disappointing sales of $149 million in the third quarter of 2024 but a recent survey by Leerink Partners of ...

Merck plans to stop a late-stage study testing ... 2025 Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates ...

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

The $36 per share, bolt-on deal helps to build Merck's R&D portfolio as it tries to reduce the proportion of sales it makes from $17 billion-plus immuno-oncology blockbuster Keytruda ...

There’s little doubt that losing evobrutinib is a heavy blow, given that Merck had been predicting sales of the drug could top $1 billion per year, despite some concerns that it could cause ...